The USC/Norris Comprehensive Cancer Center at the University of Southern California was founded in 1971 and has been continuously supported by a Cancer Center Core Support Grant since 1973. It has developed into a major regional and national resource for cancer research, treatment, prevention and education. Center facilities have been built and developed with support from the NCI, the University, and the Kenneth Norris Jr. Cancer Hospital which is an integral part of the Cancer Center. The Center is undergoing a major expansion by the addition of the Norman Topping Tower (110,000 nsf) attached to the existing headquarters building. The Center's research programs are organized into five discipline-based and four disease-based programs. The discipline-based programs are headed by senior investigators in the fields of gene regulation, cell biology, developmental therapeutics and clinical trials, cancer epidemiology and cancer control research. The disease-based programs which provide focus to our multidisciplinary research efforts are in genitourinary, gastrointestinal, breast cancer and hematologic malignancy/retroviral diseases. This application is for: 1) partial salary support for the Center's senior leadership who are responsible for planning and overseeing our research efforts; 2) support for planning and evaluation to keep the Center at the forefront of cancer research; 3) support for the administrative intrastructure of the Center; 4) partial support for the Center's 13 shared resources which facilitate the conduct of our peer-reviewed research; 5) support for developmental funds to help us recruit new investigators in areas we have targeted for expansion and to provide support for pilot projects, specifically designed to stimulate translational research. Continued funding from the Cancer Center Core Support Program will allow us to build on our strengths in molecular genetics, cell biology, cancer treatment (including gene therapy), cancer epidemiology and cancer control and to translate our underlying expertise into strong, peer-reviewed funded research programs focused on cancers of major consequence in this country.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA014089-23S1
Application #
2864792
Study Section
Cancer Centers and Research Programs Review Committee (CCRP)
Program Officer
Vembu, Devi
Project Start
1980-04-01
Project End
2000-11-30
Budget Start
1997-12-01
Budget End
1998-11-30
Support Year
23
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Southern California
Department
Biochemistry
Type
Schools of Arts and Sciences
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Liu, Minmin; Zhang, Lian; Li, Hongtao et al. (2018) Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. Hepatology 68:1412-1428
Miller, Kimberly A; Ramirez, Cynthia N; Wojcik, Katherine Y et al. (2018) Prevalence and correlates of health information-seeking among Hispanic and non-Hispanic childhood cancer survivors. Support Care Cancer 26:1305-1313
Belic, Jelena; Graf, Ricarda; Bauernhofer, Thomas et al. (2018) Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer 143:1236-1248
Tobin, Jessica; Allem, Jon-Patrick; Slaughter, Rhona et al. (2018) Posttraumatic growth among childhood cancer survivors: Associations with ethnicity, acculturation, and religious service attendance. J Psychosoc Oncol 36:175-188
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472

Showing the most recent 10 out of 842 publications